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Abstract
Aims
Likely pathogenic/pathogenic variants in genes encoding desmosomal proteins play an
important role in the pathophysiology of arrhythmogenic right ventricular cardiomyopathy
(ARVC). However, for a substantial proportion of ARVC patients, the genetic substrate
remains unknown. We hypothesized that plectin, a cytolinker protein encoded by the PLEC
gene, could play a role in ARVC because it has been proposed to link the desmosomal pro-
tein desmoplakin to the cytoskeleton and therefore has a potential function in the desmo-
somal structure.
Methods
We screened PLEC in 359 ARVC patients and compared the frequency of rare coding
PLEC variants (minor allele frequency [MAF] <0.001) between patients and controls. To
assess the frequency of rare variants in the control population, we evaluated the rare coding
variants (MAF <0.001) found in the European cohort of the Exome Aggregation Database.
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We further evaluated plectin localization by immunofluorescence in a subset of patients with
and without a PLEC variant.
Results
Forty ARVC patients carried one or more rare PLEC variants (11%, 40/359). However, rare
variants also seem to occur frequently in the control population (18%, 4754/26197 individu-
als). Nor did we find a difference in the prevalence of rare PLEC variants in ARVC patients
with or without a desmosomal likely pathogenic/pathogenic variant (14% versus 8%, respec-
tively). However, immunofluorescence analysis did show decreased plectin junctional locali-
zation in myocardial tissue from 5 ARVC patients with PLEC variants.
Conclusions
Although PLEC has been hypothesized as a promising candidate gene for ARVC, our cur-
rent study did not show an enrichment of rare PLEC variants in ARVC patients compared to
controls and therefore does not support a major role for PLEC in this disorder. Although rare
PLEC variants were associated with abnormal localization in cardiac tissue, the confluence
of data does not support a role for plectin abnormalities in ARVC development.
Introduction
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable progressive heart
condition characterized by fibro-fatty replacement of the ventricular myocardium [1]. ARVC
is most commonly transmitted as an autosomal dominant trait [2] and has an estimated preva-
lence of ~1:2500 [3]. The majority of the likely pathogenic or pathogenic variants variants
(>50%) are found in the five genes coding for the major desmosomal proteins: plakophilin-2
(PKP2), desmoplakin (DSP), desmoglein-2 (DSG2), desmocollin-2 (DSC2), and plakoglobin
(JUP) [4]. Clinically, ARVC patients suffer from ventricular arrhythmias, syncope, and sudden
cardiac death as early as young adulthood [5], with the majority of cases diagnosed before the
age of 40 years [6]. Identification of ARVC-associated variants greatly facilitates the identifica-
tion of family members at risk and provides a better understanding of the underlying patho-
physiological mechanisms [1]. However, while more ARVC-associated genes are known [7],
they only contribute to a small proportion of cases of this predominantly desmosomal disease,
and roughly half of ARVC cases remain gene elusive [8].
We wanted to explore whether the candidate gene PLEC, which encodes for plectin, under-
lies ARVC pathogenesis. Plectin is a large cytolinker protein that belongs to the plakin family
of proteins. It is believed to connect the cardiac desmosome to the cytoskeletal intermediate fil-
ament desmin via linking DSP within cardiomyocytes [9]. In cardiac tissue, plectin is mainly
localized at the intercalated disk and the sarcomeric Z-line, whereas in skin it is located at des-
mosomes and hemi-desmosomes [10]. This means that plectin potentially has a general and
fundamental role in junctional complexes [9]. PLEC is a well-known player in the skin disease
epidermolysis bullosa simplex with muscular dystrophy (EBS-MD). It is caused by compound
heterozygous or homozygous PLEC variants, and research on these conditions has led to
observations that implicated it in various forms of cardiomyopathy other than ARVC. When
fully knocked out in mice, plectin deficiency causes severe skin blistering, generalized skeletal
myopathies and ultra-structural abnormalities in the heart [11]. Striated-muscle-specific
Rare plec variants in arrhythmogenic right ventricular cardiomyopathy
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conditional Plec knock-out mice showed a decline in endurance performance and, by the age
of 16 months, an increase in connective tissue formation in the heart [12]. Sporadic cases of
cardiac involvement have also been reported in people with likely pathogenic or pathogenic
variants in PLEC. These include an EBS-MD patient with ventricular hypertrophy [13]; an
EBS-MD patient who, by the age of 30, was discovered to have asymptomatic dilated cardio-
myopathy (DCM) that later progressed to right ventricular involvement including (septal)
fibrosis [14]; an EBS-MD patient who had a left ventricular non-compaction cardiomyopathy
[15]; and a compound heterozygous carrier for two truncating PLEC variants who had DCM
and episodes of malignant ventricular arrhythmias [16].
Combining PLEC’s potential role in the desmosome with the experimental data and the
clinical reports from literature linking EBS-MD and cardiac conditions, led us to hypothesize
that plectin may play a role in the pathophysiology of, or increase the susceptibility to, ARVC.
We therefore analysed PLEC in a large group of ARVC patients, described in previous studies
[17–19], and compared this to PLEC variants found in the Exome Aggregation Consortium
dataset (ExAC) [20]. Cluster analysis was performed to identify possible hotspot regions in
PLEC. In addition, immunofluorescence analysis was performed on endomyocardial biopsies.
Results
ARVC cohort
We identified 47 ‘rare’ (population frequency<0.001) or novel coding variants in Plectin iso-
form 1 (NM_201380) and three rare variants in two other isoforms (isoform 1a [NM_201384]
and 1g [NM_201383]). For an overview of the identified rare or novel coding PLEC variants
see S1 Table. Plectin has eight isoforms that differ only in the N-terminal sequences encoded
by alternatively spliced first exons [21]. The three variants we identified in isoform 1a and 1g
were not in included in the subsequent analyses because isoform 1a is not expressed in the
heart [22] and isoform 1g does not belong to the muscle-specific set of major isoforms [9].
Of the 359 patients, 40 (11%) carried one or more rare variants: 35 carried one rare variant,
four carried two rare variants, and one carried four rare variants. Almost all were missense var-
iants (96%, 45/47), but one was an in frame insertion and one a nonsense variant. There was
no significant difference in the percentage of ARVC patients who carried one or more rare
PLEC variants between those with and without a previously identified ARVC-associated vari-
ant (14% versus 8%, respectively [Table 1]).
ExAC Eu
The median coverage of PLEC (NM_2013830) in the ExAC Eu cohort was 40x. In total, 4761
rare coding PLEC variants were found. S2 Table provides an overview of the identified variants
Table 1. Overview of proportion of individuals with one or more PLEC variant.
Cohort ARVC-NL
(n = 79)
ARVC-UK
(n = 84)
ARVC-US
(n = 196)
Total
(n = 359)
Fisher’s exact
Rare PLEC variant carriers 23%
(18/79)
8%
(7/84)
7%
(15/196)
11%
(40/359)
ARVC LP/P variant Yes No Yes No Yes No Yes No
n = 42 n = 37 n = 46 n = 38 n = 98 n = 98 n = 186 n = 173
Rare PLEC variant carriers 24% (10/42) 22% (8/37) 13% (6/46) 3% (1/38) 9% (10/98) 5% (5/98) 14% (26/186) 8% (14/173) P = 0.093
ARVC = Arrhythmogenic right ventricular cardiomyopathy, LP = likely pathogenic, n = number of subjects, P = pathogenic, PLEC = plectin
https://doi.org/10.1371/journal.pone.0203078.t001
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in the ExAC Eu dataset. Seven rare missense variants were found in the homozygous state. Of
the 4761 rare variants, 4689 were missense variants (98.5%), 42 were in frame insertions/dupli-
cation or deletions (0.9%), and 30 were truncating variants (0.6%). The estimated proportion
of individuals with a rare PLEC variant (after taking homozygous variants [n = 7] into account)
is 18% ([4761–7]/26197).
Frequency of rare PLEC variants in ARVC versus ExAC Eu
The proportion of individuals in the ARVC cohorts with one or more rare PLEC variants is
0.11 (Table 1) as compared to 0.18 in ExAC. The case excess of rare PLEC variants in the
ARVC cohort would therefore be -0.07, showing that there is no enrichment of rare PLEC
variants in ARVC patients (Table 2). Thirty-three of the 47 rare PLEC variants (70%) in the
ARVC cohort had a scaled Combined Annotation Dependent Depletion (CADD) score of 20
or more, compared to 3448 of the 4761 PLEC variants (72%) in the ExAC Eu dataset [23], indi-
cating no differences in impact of these variants between patients and controls.
Ten patients (3%, 10/359) in the ARVC cohort carried one or more unique variant(s) in
PLEC. Of these 10, six also carried a pathogenic or likely pathogenic variant associated with
ARVC. In the ExAC Eu cohort, 500 unique variants were identified, and the estimation of the
frequency of unique variants in the European general population would then be approximately
2% (500/26197).
To evaluate the possibility that having a rare PLEC variant might negatively modify disease
expression, we compared the clinical characteristics of patients who carried an ARVC-associ-
ated variant to those of patients who carried an ARVC-associated variant and a rare PLEC vari-
ant. However, the only difference we found was that patients with an ARVC-associated variant
and a rare PLEC variant were older at first presentation/evaluation compared to patients carry-
ing only an ARVC-associated variant (S3 Table). There were no differences in other markers
of clinical severity, suggesting that the presence of a PLEC variant was unlikely to be a negative
modifier of disease expression.
Nonrandom mutation cluster analysis
Of the 47 rare PLEC variants, 43 were distinct and four variants were found twice. Mapping
these 43 rare variants along the protein sequence and running the non-random mutation clus-
ter analysis with Bonferroni correction revealed no cluster formation at P value <0.1.
Immunofluorescence analysis
Analysis of immunostained myocardial tissue. Immunostained samples demonstrated
predominant junctional N-cadherin localization in myocardium, in both the PLEC negative
(group 1) and PLEC positive (group 2) ARVC patients (PLEC negative TFC+ patients, diag-
nostic score 3.3 ± 0.2 [normal]; PLEC positive TFC+ patients, diagnostic score 2.9 ± 0.4
Table 2. Odds ratio and Chi-Square test results for the proportion of carriers with one or more rare PLEC variant in ARVC cases versus ExAC European controls.
ARVC cases Controls
with a rare
PLEC
variant
without a rare
PLEC variant
Proportion of
individuals with a rare
PLEC variant
with a rare
PLEC
variant
without a rare
PLEC variant
Proportion of
individuals with a rare
PLEC variant
Case
Excess
Odds
ratio
CI
lower
CI
upper
Chi-
Square
40 319 0.11 4754 21433 0.18 -0.07 0.55 0.39 0.77 0.0002
ExAC Eu cohort.
ARVC = Arrhythmogenic right ventricular cardiomyopathy, CI = Confidence Interval, PLEC = plectin
https://doi.org/10.1371/journal.pone.0203078.t002
Rare plec variants in arrhythmogenic right ventricular cardiomyopathy
PLOS ONE | https://doi.org/10.1371/journal.pone.0203078 August 30, 2018 4 / 14
[normal]). PLEC negative TFC+ patients displayed robust junctional localization for plectin
(diagnostic score 3.3 ± 0.2 [normal]), whereas PLEC positive TFC+ patients displayed aberrant
junctional plectin localization (diagnostic score 0.7 ± 0.1 [abnormal], Fig 1A and 1B).
Inter-observer reliability analysis (%Agreement) among observers demonstrated an overall
inter-observer agreement of 91.7 ± 4.7% and 86.7 ± 9.1% for ARVC TFC+ patients without
and with a PLEC variant, respectively, for normal N-cadherin junctional localization (diagnos-
tic scores ranging from 2–4). Observers demonstrated an overall inter-observer agreement of
87.5 ± 5.2% for normal plectin junctional localization (diagnostic scores of 2–4) for ARVC
patients without an additional rare PLEC variant. Whereas, inter-observer agreement was
100.0 ± 0.0% for abnormal junctional plectin localization (diagnostic scores of 0–1) in
Fig 1. Immunohistochemical analysis of myocardium from TFC+ patients with and without a PLEC variant. (A) Representative images of
immunostained myocardium from patients from group 1 (n = 8) and group 2 (n = 5) (see also S7 Table). Of note, there is a reduced junctional signal for
plectin (white arrows) in myocardium from patients with a PLEC variant compared to patients without a PLEC variant, even though there is a normal
junctional signal for N-cadherin between groups. Scale bar, 25μm. (B) N-cadherin and plectin immunostain scores between groups (n = 3 individual
scores were recorded per data point per patient by 3 independent observers). (C) Each patient’s averaged observer scores for plectin. Averaged scores
presented as mean±SEM. P<0.0005 deemed significant for plectin-immunostained myocardium from group 1 versus group 2 using 2-tailed unpaired
t-test with equal variances.
https://doi.org/10.1371/journal.pone.0203078.g001
Rare plec variants in arrhythmogenic right ventricular cardiomyopathy
PLOS ONE | https://doi.org/10.1371/journal.pone.0203078 August 30, 2018 5 / 14
myocardium for ARVC patients carrying an additional PLEC variant (Fig 1C, S4 Table), indi-
cating that the observation of abnormal localization is not due to variation between the
observers.
Discussion
Plectin is a cytolinker protein thought to link the cytoskeleton to the cardiac desmosome.
Since the desmosomes play a key role in the pathophysiology of ARVC, we hypothesized that
ARVC patients might carry genetic PLEC variants that contribute to susceptibility to ARVC.
Based on our findings of similar frequency and location of rare PLEC variants in both patients
and controls and no striking difference in phenotypes in patients with and without PLEC vari-
ants, we conclude that PLEC variants do not play a major role in ARVC pathogenesis. Our
immunofluorescence study, however, appeared to show different plectin localization in cases
with PLEC variants, which may suggest that some variants have an effect in the heart on a
molecular level.
Rare variant frequency in patients and controls
We identified 47 rare or novel heterozygous PLEC variants in isoform 1 in TFC+ ARVC
patients, and the majority of these were missense variants. Forty (11%) of all patients carried a
rare protein-altering variant. However, based on the frequency of rare variants in controls
(ExAC Eu), it appears that many individuals in the control population also carry a rare variant
(~18%). In the context of these population data, it does not seem likely that PLEC plays a
major role in ARVC pathophysiology. This is further underscored by the fact that our cluster
analysis did not reveal any regions with rare variants that cluster in patients. We also saw no
differences in the predicted impact of protein alterations between variants identified in
patients or in controls, as comparable percentages of variants with CADD scores>20 were
found in both. This is consistent with recent work by Walsh et al showing that some cardiomy-
opathy-related genes (MYBPC3,MYH6, and SCN5A) show little or no excess burden of vari-
ants in DCM patients [24]. This suggests that most variants in these genes are not associated
with DCM, although we know that some specific variants are definitely involved [24]. We
therefore cannot exclude that some identified PLEC variants may have an effect on the devel-
opment of ARVC or another type of cardiomyopathy. This was, for example, suggested in a
patient with skin blistering and DCM, who was compound heterozygous for a truncating and
missense variant in PLEC [14]. As skin blistering in these patients is generally related to homo-
zygous or compound heterozygous PLEC variants, this suggests that in this case the missense
variant does play a role and contributes to the phenotype. Moreover, a missense variant in
exon 31 of PLEC has been described to cause an autosomal dominant form of skin disease,
EBS-Ogna [25], which manifests exclusively as skin fragility. This missense variant leads to
selective proteolysis of isoform 1a, and thus deficiency in this isoform, resulting in reduced lev-
els and dysfunction of hemi-desmosomes [26]. Similar to what occurs in EBS-Ogna, it could
be that some other rare PLEC missense variants increase the proteolysis of plectin in the heart
and thereby diminish the mechanical coupling. Moreover, heterozygous missense variants
were also recently shown to play a role in EBS [27]. Our patients, however, exhibited no strik-
ing skin blistering.
Clinical characteristics
The older age at presentation/evaluation and similar occurrence of life-threatening arrhyth-
mias during presentation/evaluation in the cohort of patients who carry an ARVC-associated
variant and a rare PLEC variant compared to that of the cohort of patients carrying only an
Rare plec variants in arrhythmogenic right ventricular cardiomyopathy
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ARVC-associated variant does also not support a major role for PLEC as a negative disease
modifier in ARVC. In fact, a possible protective effect of carrying a rare PLEC variant cannot
yet be ruled out.
Immunofluorescence: Evidence for mechanistic effects
In comparison to our other results, our immunofluorescence analysis showed abnormal
localization of plectin in hearts of patients with a PLEC variant. As localization of plectin was
normal in ARVC patients with or without a desmosomal likely pathogenic/pathogenic variant
(PLEC-variant negative), abnormal localization of this protein is not a general phenomenon in
ARVC patients. Moreover, the fact that the PKP2 pathogenic variants, c.2146-1G>C and
c.148_151delACAG, p.Thr50Serfs61, were present in both ARVC subgroups (those with and
without a rare PLEC variant) studied with immunohistochemistry suggests that abnormal
plectin localization is also not specifically related to desmosomal variants. In a previous report
on EBS patients carrying heterozygous missense PLEC variants, immunofluorescence analyses
of skin biopsies also showed a decreased signal for plectin [27]. Taken together, these results
suggest that the presence of rare PLEC variants is accountable for abnormal plectin expression
and localization, although this mislocalization may not be sufficient to directly cause ARVC.
In the skin, plectin is a crucial component of the hemidesmosomes (HDs), and HDs con-
nect the epidermis to the extracellular matrix [9]. Plectin insufficiency in the skin results in
reduced number of HDs and skin fragility [28]. In the cardiomyocyte, the binding partners of
plectin are less well known. In vivo studies have shown that plectin is closely associated with
desmosomes, while in vitro analyses have shown that plectin molecules are biochemically con-
nected to desmoplakin [29]. In addition, the loss of co-localization of plectin and desmin at
the Z-discs and intercalated disc, together with desmin and plectin aggregate formation,
observed in the heart of the patient with EBS-MD and DCM indicates that plectin plays an
important role in the structural organization of the desmin network and in providing mechan-
ical support [14]. We know that plectin contains a number of plakin repeat domains, typical of
desmosomal proteins and responsible for binding intermediate filaments, as well as a highly
variable N-terminal actin-binding domain [30]. By binding both intermediate filaments and
myofilaments, it is possible that plectin attracts the structurally robust desmosomes around the
more fragile adherens junctions at the cardiac intercalated disks and thus provides the conti-
nuity between myofibrils of neighbouring cardiomyocytes. The abnormal localization of plec-
tin seen in our immunofluorescence analysis could reflect the decrease of its interjunctional
linking capacity, which could mean the adherens junctions are less supported by desmosomes
and thus more sensitive to stress and damage. One can theorize that this could be a factor that
lowers the threshold for developing ARVC. However it is unlikely that these changes on their
own are responsible for the development of ARVC, since some of the variants we analysed
with immunofluorescence also occurred relatively frequently in the general population (S7
Table), and two occurred even in homozygous state. This, however, does not mean these vari-
ants do not have an effect. A heterozygous missense variant that is found relatively often in the
European population (MAF = 0.081%) demonstrated a decreased signal for plectin in the skin
of a patient with EBS [27]. Additionally, the PLEC missense variant (c.1298G>A) described in
the EBS-MD patient with DCM has a relatively high MAF (1.9% in ExAC Eu) [14]. This sug-
gests that, in combination with another variant, even a relatively common PLEC variant could
function as a genetic modifier. In line with this, a recent genome-wide association study identi-
fied a missense variant in PLEC (MAF 1.2% in Iceland) associated with atrial fibrillation, albeit
with a small effect size [31]. However, in order to investigate a putative risk factor/modifier
role of PLEC variants in ARVC, a much larger sample size is needed. Thus, while the presence
Rare plec variants in arrhythmogenic right ventricular cardiomyopathy
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of PLEC variants in the general population suggest it is not a major player in the pathogenesis
of ARVC, it seems that a small sub-set of variants do appear have a mechanistic role that may
be additive. Future research on ARVC should keep this in mind when looking at cases with a
PLEC variant.
Conclusion
In a large cohort of patients with ARVC, we could not confirm a major role for PLEC, a prom-
ising candidate gene due to its cytolinking connection to the cardiac desmosome. Some PLEC
variants, however, are associated with plectin mislocalization, and the association of these
changes with ARVC requires further investigation.
Limitations
We used the ExAC database as a control cohort. However, the ExAC database contains aggre-
gated data, which means it is not possible to evaluate data at an individual level. The frequency
of rare variants in PLEC that we estimated from ExAC is therefore an approximation based on
the assumption that each rare variant is carried by only one individual. This likely an overesti-
mation as we found 88% of our ARVC cohort carried one rare variant while 12% carried more
than one rare variant (4 patients carried two variants and 1 patient carried four). However, if
we make an estimation assuming that in the ExAC cohort 50% of the individuals carry one
rare variant, 25% carry two rare variants and 25% carry three rare variants, the proportion of
individuals in ExAC Eu with rare variants would still be 13% (compared to 11% in the ARVC
cohort).
The proportion of individuals in the Dutch ARVC cohort with a rare PLEC variant is signif-
icantly higher compared to the US and UK cohort. This is likely due to the fact that the ExAC
Eu cohort for a significant proportion consists of data of individuals from the US and UK.
Identified PLEC variants in the UK and US ARVC cohorts are therefore more likely to be fil-
tered out, resulting in a lower proportion of these individuals with a rare PLEC variant com-
pared to Dutch individuals. Although we also used the Genome of the Netherlands database
(n = ~500 individuals) to filter out common variants specific for the Dutch population, the rel-
ative small size of this database is likely to lead to an overestimation of rare PLEC variants in
the Dutch ARVC cohort compared to the US and UK cohort.
As also mentioned above, absence of enrichment of rare variants in patients versus controls
does not exclude the possibility that some specific variants may have an effect. To evaluate a
possible effect one should assess each variant separately. This would, however, require a high
workload of segregation analyses and functional studies in which the chance of finding a
significant result would still be low. The immunofluorescence results however are interesting
to follow-up. The limitations of these results currently cannot distinguish between abnormal
localization due to a general underlying mechanism or abnormal localization due to the
specific PLEC variant (or combination of variants). To truly obtain more insight we would
have to analyse healthy hearts of carriers with rare PLEC variants, samples which are not avail-
able to us.
Materials and methods
Patients
Dutch (NL) cohort. Seventy-nine patients were included of whom 75 were diagnosed
with definite ARVC according to the revised 2010 Task Force Criteria (TFC+) for ARVC [32].
In three patients, a borderline diagnosis of ARVC was made. A biopsy from another patient
Rare plec variants in arrhythmogenic right ventricular cardiomyopathy
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showed fibrosis and adipocyte accumulation with atrophy of the myocytes fitting the diagnosis
of ARVC (major TFC criterion). The majority of patients were previously screened for variants
in desmosomal genes. Some individuals were not screened for all desmosomal genes, either
because of the identification of a pathogenic variant in an ARVC-associated gene or because
family members with ARVC were shown to be variant-negative for those genes. For a detailed
description of the number of patients analysed for the different desmosomal genes see S5
Table. In 42 patients (53%) a likely pathogenic or pathogenic variant associated with ARVC
was identified, classified following the guidelines from the American College of Medical
Genetics [33]: 29 in PKP2, 10 in PLN, two in DSG2, and one in SCN5A.
United Kingdom (UK) cohort. The British cohort included 84 TFC+ patients. Forty-six
patients (55%) carried a likely pathogenic or pathogenic variant associated with ARVC: 26 in
PKP2, nine in DSP, eight in DSG2, one in DSC2, one in LMNA, and one digenic in DSC2 and
SCN5A.
United States (US) cohort. In total 196 TFC+ US patients were included. Ninety-eight
patients (50%) carried a pathogenic or likely pathogenic desmosomal variant: 76 in PKP2, five
in DSP, seven in DSG2 (three compound heterozygous), three in DSC2 (one compound hetero-
zygous), two in PLN, two in SCN5A, one in TMEM43, and two digenic (one in SCN5A and
LMNA and one in PKP2 and DSG2).
ExAC European cohort (ExAC Eu). Genetic variants of PLEC (transcript ID
ENST00000322810.8, RefSeq NM_201380) were downloaded from the ExAC database (http://
exac.broadinstitute.org, version 0.3.1). Since our cohort mainly consisted of patients of Euro-
pean descent (S6 Table), we used the genetic data from individuals of European descent (non-
Finnish) in the ExAC cohort (ExAC Eu).
Genetic analysis. Genomic DNA was isolated from blood samples using standardized
procedures. Written informed consent was obtained from all participants following local med-
ical ethics committee guidelines. The study was approved by the relevant National Research
Ethics Service (NRES) committee of the NHS Health Research Authority, the Johns Hopkins
School of Medicine Institutional Review Board, and the METc boards of the University Medial
Centers of Groningen, Utrecht, and Amsterdam. Our study and all experiments conformed
with the principles of the Declaration of Helsinki. In 66 Dutch patients, PLEC was analysed by
Sanger sequencing. Primers for PCR amplification of the coding regions of the PLEC gene
were designed to encompass the coding exons as well as adjacent intronic sequences as
described previously [27]. Amplifications were conducted following a standard PCR protocol
and PCR products were confirmed by direct Sanger sequencing. The remainder of the Dutch
patients, the UK and the US patients were all screened with targeted gene panel sequencing
(PLEC included—list of genes included in panels available on request) or by whole exome
sequencing with results then confirmed via Sanger sequencing.
Data analysis
Variant analysis: ARVC cohorts. Chromosomal positions of variants of the PLEC gene
identified in the three ARVC cohorts (NL, UK and US) were annotated with information from
the ExAC database using an in-house developed script and frequency information on these
variants were collected. Variant annotation is according to the NM_201380 isoform unless
otherwise indicated. All variants found in the ARVC cohorts with a MAF <0.001 in the ExAC
Eu dataset were included for further analysis. These included missense, in-frame insertions/
deletions, frame-shift, nonsense variants, and variants affecting the consensus RNA splice
donor and acceptor sites (first and last two bases of each intron). Additionally PLEC variants
identified in the Dutch cohort with a MAF <0.001 in the Genome of the Netherlands database
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(http://www.nlgenome.nl/) were excluded. The NL, UK, and US ARVC cohorts were com-
bined and analysed as one cohort (ARVC cohort, n = 359).
Variant analysis: ExAC Eu. Only high-quality (Pass filter) PLEC variants found in the
ExAC Eu subpopulation were used. All variants (variant types as indicated above) in the desig-
nated canonical transcript (NM_201380) with a MAF <0.001 were included for further
analysis.
Proportion of individuals with a rare PLEC variant. The proportion of individuals with
rare PLEC variants in the ExAC Eu dataset was calculated by dividing the sum of the adjusted
allele count by the mean of the total adjusted alleles divided by two, as previously described
[24]. The frequency of carriers of rare variants in the ARVC cohort was calculated by dividing
the sum of patients with one or more rare PLEC variants by the total number of ARVC patients
analysed for PLEC.
Comparison of rare variation between ARVC and ExAC Eu. The proportion of carriers
of rare variants in the ARVC cohort was compared with that in ExAC Eu. Case excess was
defined by subtracting the proportion of individuals in ExAC Eu with a rare variant from the
proportion of individuals carrying a rare PLEC variant in the ARVC cohort. We calculated the
odds ratio (OR) with 95% confidence intervals.
Cluster analysis. To identify putative clustering of rare missense variants in PLEC, dis-
tinct rare variants were mapped along the protein sequence. Nonrandom mutation cluster,
implemented in the iPAC Bioconductor R package, was used to identify clusters of variants in
the ARVC cohort [34].
Immunofluorescence analysis
Cohort selection and patient myocardial samples. Endomyocardial biopsies were
obtained from 13 US patients. Group 1 (n = 8) consisted of TFC+ ARVC patients with no
PLEC variant (five with PKP2 variants, one with compound heterozygous variants in DSG2,
and two with no pathogenic/likely pathogenic variant identified). Group 2 included TFC+
ARVC patients who either had a variant in PLEC alone (n = 3) or a variant in PLEC and a likely
pathogenic/pathogenic variant in PKP2 (n = 2). The specific desmosomal variants and PLEC
variants are documented in S7 Table.
Immunostaining myocardial samples. Patient myocardial samples were formalin-fixed,
paraffin-embedded, cut at a 5μm thickness and mounted on clear, plus microscope slides.
Slides were deparaffinized, rehydrated, underwent antigen retrieval, then blocked at room
temperature for one hour as previously described [35]. Slides were incubated overnight at 4˚C
with mouse anti-N-cadherin (Santa Cruz, sc-59987; 1:500) or rabbit anti-Plectin (Cell Signal-
ling, cs-D6A11; 1:400). The following day, slides were washed and incubated with secondary
antibodies (donkey anti-mouse Alexa Fluor-647 [Invitrogen, A31571; 1:500] and goat anti-
rabbit Alexa Fluor-488 [Invitrogen, A11070; 1:500]), washed and cover-slipped with mounting
media (Fluoroshield with DAPI, Sigma F6057). Immunoreactive signal was visualized using a
Leica TCS SPE RGBV confocal microscope (Leica Microsystems) at 40X magnification. Slides
were coded and analysed in a blinded fashion by three independent observers.
Analysis of immunostained myocardial samples. Slides were imaged, coded, and dis-
tributed to three independent, blinded observers and graded as previously described [35,36].
Observers were requested to score samples into one of five diagnostic classes: (0) no myocyte
junction plectin staining; (1) rare junction, predominantly cytoplasmic plectin staining; (2)
even mix of junction and cytoplasmic plectin staining (odds 50:50); (3) mildly reduced junc-
tion, rare cytoplasmic plectin staining; or (4) robust plectin staining, only at cell-cell junctions.
Observers were additionally requested to classify patient samples for junctional distribution of
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N-cadherin using the five diagnostic classes described above. All three observer scores were
recorded and averaged for each individual patient (n = 3 different observer scores/patient/
immunostain), then averaged by immunohistochemical stain and by group. In addition,
observer scores were compared between observers and percent agreement was determined, as
described previously [37].
Statistical analysis
Data are presented as mean ± SEM, and a P value<0.05 was considered significant. Associa-
tions between continuous dependent variables were analysed using 2-tailed t-test (binary inde-
pendent variables) or 2-way ANOVA (2 or more variables). Fisher’s exact test was used for
comparing frequencies.
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